Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q12860

UPID:
CNTN1_HUMAN

ALTERNATIVE NAMES:
Glycoprotein gp135; Neural cell surface protein F3

ALTERNATIVE UPACC:
Q12860; A8K0H9; A8K0Y3; Q12861; Q14030; Q7M4P0; Q8N466

BACKGROUND:
Contactin-1, identified by its alternative names Glycoprotein gp135 and Neural cell surface protein F3, is integral to nervous system development. It mediates cell surface interactions, contributing to the formation of paranodal axo-glial junctions and the signaling process between axons and myelinating glial cells. Its interaction with proteins like CNTNAP1 and NOTCH1 underscores its role in oligodendrocyte generation and nervous system development.

THERAPEUTIC SIGNIFICANCE:
Given Contactin-1's critical role in Congenital myopathy 12, a disorder characterized by severe muscle weakness and disruption of muscle sarcomeres, its study is vital. Understanding the role of Contactin-1 could open doors to potential therapeutic strategies, offering hope for advancements in muscle disorder treatments and nerve repair.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.